Search

Introduction: High antioxidant capacities have been linked to the treatment of rheumatic diseases and also in the inhibition of microbial growth. Although Cakile maritima has a high antioxidant capacity, it is yet to be tested for the ability to inhibit the growth of the bacterial triggers of autoimmune inflammatory diseases. Methods: C. maritima solvent extracts were analysed for antioxidant capacity by the DPPH free radical scavenging assay. Growth inhibitory activities against bacterial species associated with initiating rheumatoid arthritis, ankylosing spondylitis and multiple sclerosis were determined by disc diffusion assay and quantified by MIC determination. Toxicity was determined by Artemia franciscana bioassay. Results: All C. maritima solvent extracts displayed good DPPH radical scavenging activity, although the ethyl acetate extract was particularly potent with an IC50 values of 3.4 μg/mL. The other extracts also had significant radical scavenging activity, with IC50 between 4.7 and 13.6 μg/mL. The bacterial growth inhibitory activity of the extracts correlated with their free radical scavenging activity. The ethyl acetate extract displayed the most potent growth inhibitory activity against most bacterial species. This extract was particularly potent against Proteus mirabilis, Proteus vulgaris and Pseudomonas aeruginosa (MIC values of 431, 559 and 777 μg/mL, respectively). The hexane extract was also a potent inhibitor of the Proteus spp., (MIC of approximately 500-800 μg/mL). The ethyl acetate extract also inhibited Klebsiella pneumoniae growth, albeit with higher MIC's (approximately 1500 μg/mL). All other C. maritima extract-bacteria combinations generally resulted in mid-low potency inhibition. All of the extracts were determined to be nontoxicin with the Artemia franciscana bioassay, with LC50 values substantially >1000 μg/mL. A total of 97 unique mass signals were detected in the C. maritima ethyl acetate extract by nonbiased GC-MS headspace analysis. A number of terpenoids which may contribute to the therapeutic bioactivities of the extract were putatively identified. Conclusion: The lack of toxicity and the inhibitory activity against microbial triggers of rheumatoid arthritis, ankylosing spondylitis and multiple sclerosis by the C. maritima ethyl acetate extract indicates its potential in the treatment and prevention of these diseases. [ABSTRACT FROM AUTHOR]

Introduction: Myrrh has been used traditionally for the inhibition of microbial growth and for the treatment of rheumatic diseases. Despite this, myrrh extracts are yet to be tested for the ability to inhibit the growth of the bacterial triggers of autoimmune inflammatory diseases. Methods: Solvent extracts prepared from commercially obtained myrrh resin were analysed for the ability to inhibit the growth of bacterial species associated with initiating rheumatoid arthritis (P. mirabilis), ankylosing spondylitis (K. pneumoniae) and multiple sclerosis (A. baylyi, P. aeruginosa) by disc diffusion assay, and quantified by MIC determination. Toxicity was determined by Artemia franciscana bioassay. The most potent inhibitory extract was investigated using non-targeted GC-MS head space analysis (with screening against a compound database) for the identification and characterisation of individual components in the crude plant extracts. Results: Methanolic myrrh extract inhibited the growth of all bacterial species tested. The growth inhibition of this extract was particularly notable against P. mirabilis and K. pneumoniae, with MIC values substantially < 1000 µg/mL for both reference and clinical bacterial strains. Indeed, the MIC values of the methanolic extract against P. mirabilis reference and clinical strains were 572 and 463 µg/mL respectively. The methanolic extract also inhibited the growth of A. baylyi (MIC approximately 3000 µg/mL) and P. aeruginosa (MIC approximately 1800 µg/mL). However, the MICs against these bacteria was indicative of only moderate inhibitory activity. The aqueous, ethyl acetate, chloroform and hexane extracts also inhibited the growth of all bacterial species, albeit with moderate (MIC values 1000-5000 µg/mL) to low efficacy (MIC values >5000 µg/mL) against all bacterial species. All myrrh extracts were non-toxicin the Artemia franciscana bioassay, with LC50 values substantially above 1000 µg/mL. Non-biased GC-MS headspace analysis of the methanolic extracti dentified a high diversity of monoterpenoids and sesquiterpenoid. Conclusion: The lack of toxicity and the inhibitory activity of the methanolic myrrh extract against microbial triggers of rheumatoid arthritis, ankylosing spondylitis and multiple sclerosis indicates its potential in the treatment and prevention of these diseases. [ABSTRACT FROM AUTHOR]

Introduction: Frankincense has been used traditionally for the inhibition of microbial growth and for the treatment of rheumatic diseases. Despite this, frankincense extracts are yet to be tested for the ability to inhibit the growth of the bacterial triggers of autoimmune inflammatory diseases. Methods: Solvent extracts prepared from commercially obtained frankincense were analysed for the ability to inhibit the growth of bacterial species associated with initiating rheumatoid arthritis (P. mirabilis), ankylosing spondylitis (K. pneumoniae) and multiple sclerosis (A. baylyi, P. aeruginosa) by disc diffusion assay, and quantified by MIC determination. Toxicity was determined by Artemia franciscana bioassay.The most potent inhibitory extracts were investigated using non-targeted GC-MS head space analysis (with screening against a compound database) for the identification and characterisation of individual components in the crude plant extracts. Results: Methanolic and aqueous frankincense extracts inhibited the growth of all bacterial species. The growth inhibition of these extracts was particularly notable against P. mirabilis and K. pneumoniae, with MIC values generally ⩽ 1000 μg/mL for both reference and clinical bacterial strains. Indeed, the MIC values of the methanolic extract against P. mirabilis, and for the aqueous extract against K. pneumonia, were as low as 59.6 and 75.2 μg/mL respectively. The methanolic and aqueous extracts also inhibited the growth of A. baylyi and P. aeruginosa. However, with the exception of the growth inhibition of A. baylyi by the aqueous extract (MIC=4313 μg/mL: moderate inhibitory activity), the MICs against these bacteria was indicative of only low inhibitory activity. The ethyl acetate, chloroform and hexane extracts also inhibited the growth of all bacterial species, albeit with low efficacy (MIC values generally >5000 μg/mL against all bacterial species). All frankincense extracts were non-toxic in the Artemia franciscana bioassay, with LC50 values substantially above 1000 μg/mL. Non-biased GC-MS headspace analysis of the methanolic and aqueous extracts putatively identified a high diversity of monoterpenoids and sesquiteriterpenoids. Conclusion: The lack of toxicity and the inhibitory activity of the methanolic and aqueous frankincense extracts against microbial triggers of rheumatoid arthritis and ankylosing spondylitis indicates their potential in the treatment and prevention of these diseases. [ABSTRACT FROM AUTHOR]